Attention Deficit Hyperactivity Disorder
Conditions
Keywords
ADHD, Methylphenidate, Amphetamine, Attention Deficit Hyperactivity Disorder, Treatment
Brief summary
This is a 6-month trial in adults to find out if certain neuromarkers can predict individual treatment response to stimulant medications for Attention Deficit Hyperactivity Disorder (ADHD). Males and females, ages 18-45, will complete an MRI scan at MIT prior to beginning medication for ADHD as determined by a treating clinician outside the context of this study.
Interventions
RADIATIONMRI
All participants will perform one MRI session before initiation of treatment. The imaging session will last about an hour including the structural and functional MRI portions. The subjects lie on a padded scanner couch in a dimly illuminated room, and wear foam earplugs to attenuate scanner sounds.
Sponsors
Massachusetts Institute of Technology
Massachusetts General Hospital
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
No
Inclusion criteria
* Male and female adults ages 18-55 * A diagnosis of DSM-V ADHD based on clinical assessment supported by the ADHD module of a structured diagnostic interview * Proficiency in English * Right-handed
Exclusion criteria
* Any contraindication for the use of a stimulant medication * Investigator and his/her immediate family (spouse, parent, child, grandparent, or grandchild) * Any contraindications for MRI examination (metallic implants, such as pacemakers, surgical aneurysm clips, or known metal fragments in the body) * Women who are currently pregnant or breastfeeding, as confirmed by a urine pregnancy test * Clinically significant abnormal baseline laboratory values, including systolic and diastolic blood pressure parameters above 140 and 90, respectively and resting heart rate outside 60-100 bpm
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| ADHD Clinical Global Impressions Scale - Severity (CGI-S) | 6 months | The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment. |
| ADHD Clinical Global Impressions Scale - Improvement (CGI-I) | 6 months | The Clinical Global Impression - Improvement scale (CGI-I) is a 7-point scale that requires the clinician to assess how the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Connectomic Variation Prediction of Medicine Response | 6 months | Examine whether variation in baseline ADHD severity scores and functional connectivity and structural connectivity predict whether an individual ADHD patient will respond better to one of the other stimulant family treatment, both, or neither. An MRI will be completed prior to starting medication. |
Countries
United States
Outcome results
None listed